NEW YORK, NY / ACCESSWIRE / September 25, 2019 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.
3M Company (MMM)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/3m-company-loss-submission-form?prid=3694&wire=1
Lead Plaintiff Deadline: September 27, 2019
Class Period: February 9, 2017 to May 28, 2019
Allegations against MMM include that: (i) 3M had vast internal evidence dating back decades confirming that polyfluoroalkyl substances ("PFAS") are toxic (which was first publicly revealed in February 2018 by Minnesota's Attorney General); (ii) 3M had a decades-long history of suppressing negative information and/or damaging data about PFAS; and (iii) 3M has legal exposure to state, county, and local governments and individuals around the country as a result of its knowledge and intentional concealment of the toxic harm caused by the use of PFAS.
Cardinal Health, Inc. (CAH)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/cardinal-health-inc-loss-submission-form?prid=3694&wire=1
Lead Plaintiff Deadline: September 30, 2019
Class Period: March 2, 2015 to May 2, 2018
Allegations against CAH include that: 1) following Cardinal's acquisition of Cordis, the RFID [radio-frequency identification] inventory tracking technology and advanced supply chain solutions that Defendants told investors the Company would to use to improve Cordis's performance were never implemented across Cordis; 2) Cordis's antiquated and ineffective global supply chain was causing operational and inventory problems at Cordis; 3) as a result, Cordis manufactured and accumulated excessive amounts of cardiovascular product inventories, which sat on the shelf and became unsellable and/or expired; 4) the Company materially overstated Cordis's inventory balances; 5) Cordis was not "performing well" and its integration was not "on track," "going incredibly well" or "largely on plan"; and 6) to correct Cordis's deficiencies, the Company would have to make substantial investments in Cordis's IT and supporting infrastructure, thereby incurring significant Selling, General and Administrative Expenses charges beyond the levels internally budgeted or projected by Cardinal and diminishing operating earnings.
Sarepta Therapeutics, Inc. (SRPT)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/sarepta-therapeutics-inc-loss-submission-form?prid=3694&wire=1
Lead Plaintiff Deadline: October 29, 2019
Class Period: September 6, 2017 to August 19, 2019
Allegations against SRPT include that: (i) golodirsen, Sarepta's drug for the treatment of Duchenne muscular dystrophy, posed significant safety risks to patients; (ii) consequently, the New Drug Application package for golodirsen's accelerated approval was unlikely to receive Food and Drug Administration approval; and (iii) as a result, Sarepta's public statements were materially false and misleading at all relevant times.
To learn more contact Vincent Wong, Esq. either via email email@example.com or by telephone at 212.425.1140.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
Vincent Wong, Esq.
39 East Broadway
New York, NY 10002
SOURCE: The Law Offices of Vincent Wong
View source version on accesswire.com: